News

Sanofi to acquire Origimm Biotechnology and with it novel therapeutic vaccine ORI-001 for acne vulgaris.

Read time: 1 mins

Published:3rd Dec 2021

Sanofi announced that it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.

With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline. The transaction will add ORI 001 to Sanofi’s early-stage pipeline. ORIm001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Phase 1/II trial to start in 2023.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 mins

Industry news

Antibe Therapeutics has receiver appointed.

Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved

1 min

Industry news

TreeFrog Therapeutics licenses C-Stem technology to Vertex Pharma

Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D)

1 min

See all news